What is HC Wainwright’s Estimate for ARTV FY2030 Earnings?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at HC Wainwright issued their FY2030 EPS estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.41) for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

Other analysts also recently issued research reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 17th. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Thursday, October 30th. Finally, Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Artiva Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $19.00.

Artiva Biotherapeutics Trading Down 2.1%

NASDAQ ARTV opened at $4.68 on Tuesday. The firm has a market cap of $114.89 million, a PE ratio of -1.81 and a beta of 2.92. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $7.36. The stock has a 50-day moving average of $4.12 and a 200-day moving average of $3.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, November 12th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04.

Institutional Trading of Artiva Biotherapeutics

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC lifted its position in Artiva Biotherapeutics by 419.3% during the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after acquiring an additional 117,733 shares in the last quarter. Marshall Wace LLP purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at about $79,000. Jane Street Group LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Artiva Biotherapeutics in the third quarter worth about $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.